Form 4: Third Harmonic Bio Director Acquires Stock Options
SEC Form 4 Filing
Mark T Iwicki, a director of Third Harmonic Bio, Inc., acquired 20,000 stock options on June 6, 2024.
Summary
- On June 6, 2024, Mark T Iwicki, a director of Third Harmonic Bio, Inc., acquired 20,000 stock options.
- The exercise price of these options is $13.85.
- The options vest fully on the earlier of June 6, 2025, or the next annual meeting of the Issuer's stockholders, contingent on continued service to the Issuer.
- The options expire on June 5, 2034.
- Following the transaction, Iwicki directly owns 20,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, so the sentiment is neutral.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the stock option transaction |
| 06/06/2025 | Earliest vesting date for the stock options |
| 06/05/2034 | Expiration date for the stock options |
| 06/10/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.